

## FIRST TIME GENERIC APPROVAL

<b>Brand Name</b>	Nexavar®
<b>Generic Name</b>	sorafenib tosylate
<b>Drug Manufacturer</b>	Mylan Pharmaceuticals Inc.

### New Drug Approval

#### TYPE OF CLINICAL UPDATE

First Time Generic

#### FDA APPROVAL DATE

September 10, 2020

#### LAUNCH DATE

June 1, 2022

#### REVIEW DESIGNATION

Standard

#### TYPE OF REVIEW

Abbreviated New Drug Application (ANDA): 207012

#### DISPENSING RESTRICTIONS

N/A

### Overview

#### INDICATION FOR USE

Sorafenib tablets are a kinase inhibitor indicated for the treatment of:

- Unresectable hepatocellular carcinoma
- Advanced renal cell carcinoma
- Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment.

#### MECHANISMS OF ACTION

Sorafenib is a kinase inhibitor that decreases tumor cell proliferation *in vitro*. Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, RET, RET/PTC, VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-β). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumor growth of HCC, RCC, and DTC human tumor xenografts in immunocompromised mice. Reductions in tumor angiogenesis were seen in models of HCC and RCC upon sorafenib treatment and increases in tumor apoptosis were observed in models of HCC, RCC, and DTC.

#### DOSE FORM AND STRENGTH

Tablets: 200 mg

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.

## FIRST TIME GENERIC APPROVAL

### DOSE & ADMINISTRATION

The recommended dosage is 400 mg orally twice daily without food.

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.